Immune memory to hepatitis B virus in 4-to-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine
| Autor: | Peter Soemantri, Detlef Grunert, Uwe Goering, Karl Heinz Laakmann, Rudolf Kappes, Michael Zinke, Jeanne M Jacquet, Britta Gartner, Anke Paulus Koschik, Johann Disselhoff, Ramakrishnan Gunasekaran, Klaus Kindler |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Booster vaccination Time Factors Immunology Immunological memory Diphtheria-Tetanus-acellular Pertussis Vaccines medicine.disease_cause complex mixtures Immunity medicine Humans Vaccines Combined Hepatitis B Antibodies General Pharmacology Toxicology and Pharmaceutics Child Haemophilus Vaccines Hepatitis B virus biology business.industry Dtpa hbv ipv hib virus diseases Hepatitis B medicine.disease Virology digestive system diseases Poliomyelitis Poliovirus Vaccine Inactivated Child Preschool biology.protein Female Antibody business Immunologic Memory |
| Zdroj: | Human Vaccines. 5:592-598 |
| ISSN: | 1554-8619 1554-8600 |
| DOI: | 10.4161/hv.9051 |
| Popis: | The combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine produces similar hepatitis B responses as the HBV monovalent vaccine. Booster vaccination of immunocompetent individuals primed against hepatitis B in infancy is currently not recommended. We investigated persisting immunity to hepatitis B in 4-6 (Study A; 106745) and 7-9 (Study B; 106744) year-old children primed in infancy and boosted in the second year of life with DTPa-HBV-IPV/Hib. Immunity was assessed by measuring persisting anti-HBs antibodies and evaluating the response to a challenge dose of HBV vaccine. At 4-6 years of age 86.0% of 186 subjects had persisting anti-HBsor =10 mIU/ml increasing to 98.4% after the challenge. At 7-9 years of age, 78.0% of 186 subjects continued to have anti-HBs antibody concentrationsor =10 mIU/ml, increasing to 98.9% after the challenge. In both studies anti-HBs antibody GMC rose80-fold. An anamnestic response to the HBV challenge was observed in 95.7% and 98.9% of subjects in Studies A and B, respectively. In both studies, 87% of 38 subjects with initially undetectable circulating anti-HBs antibodies (3.3 IU/ml) achieved the 10 mIU/ml threshold after challenge;or =97.0% of subjects with detectable antibodies before the challenge at least quadrupled their concentration. Post-vaccination anti-HBs concentrations were directly related to persisting antibody concentrations and the concentrations achieved after the booster dose in the second year of life. The HBV vaccine challenge dose was well tolerated. These studies show that primary and booster vaccination with combined DTPa-HBV-IPV/Hib (Infanrix hexa) induces sustained immune memory against hepatitis B up to age 9 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|